Catherine Jacob-Dolan, Darren Ty, David Hope, Katherine McMahan, Jinyan Liu, Olivia C Powers, Catherine A Cotter, Michela Sciacca, Cindy Wu, Erica Borducchi, Emily Bouffard, Hannah Richter, Jason Velasco, Elyse Teow, Mona Boursiquot, Anthony Cook, Karen Feliciano, Jake Yalley-Ogunro, Michael S Seaman, Laurent Pessiant, Mark G Lewis, Hanne Andersen, Bernard Moss, Dan H Barouch
The 2022-2023 mpox outbreak triggered vaccination efforts using smallpox vaccines that were approved for mpox, including modified vaccinia Ankara (MVA; JYNNEOS), which is a safer alternative to live replicating vaccinia virus (ACAM2000). Here, we compare the immunogenicity and protective efficacy of JYNNEOS by the subcutaneous or intradermal routes, ACAM2000 by the percutaneous route, and subunit Ad35 vector-based L1R/B5R or L1R/B5R/A27L/A33R vaccines by the intramuscular route in rhesus macaques. All vaccines provided robust protection against high-dose intravenous mpox virus challenge with the current outbreak strain, with ACAM2000 providing near complete protection and JYNNEOS and Ad35 vaccines providing robust but incomplete protection...
March 27, 2024: Science Translational Medicine